Neoprobe licenses AstraZeneca's Alzheimer plaque imaging agent
from Genetic Engineering & Biotechnology News
Neoprobe paid AstraZeneca $5 million up front for a license to the latter's late-stage radiopharmaceutical imaging candidate AZD4694, for use in positron emission tomography diagnostic imaging of amyloid plaques in Alzheimer disease patients. Under terms of the deal Neoprobe will take on clinical development and commercialization of the fluorine-18-labelled radiotracer, and expects to start a Phase III clinical program during early 2013.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063